NCT00617253View on ClinicalTrials.gov

Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 12, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
CancerRenal Cell Carcinoma
Interventions
DRUG

recombinant interleukin-21

3 mcg/kg, s.c. injection

DRUG

sunitinib

Hard gelatine capsules, 12.5 mg

DRUG

recombinant interleukin-21

10 mcg/kg, s.c. injection

DRUG

recombinant interleukin-21

30 mcg/kg, s.c. injection

DRUG

recombinant interleukin-21

100 mcg/kg, s.c. injection

Trial Locations (5)

20246

Novo Nordisk Investigational Site, Hamburg

30625

Novo Nordisk Investigational Site, Hanover

60488

Novo Nordisk Investigational Site, Frankfurt

1066 CX

Novo Nordisk Investigational Site, Amsterdam

6525 GA

Novo Nordisk Investigational Site, Nijmegen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00617253 - Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | Biotech Hunter | Biotech Hunter